What is the survival rate for triple negative metastatic breast cancer? The 5-year overall survival rate in metastatic triple-negative breast cancer (mTNBC) patients was 4–20% in western countries3,9,10,11,12,13. In Taiwan, patients with TNBC account for 15–20% of all breast cancer patients14,15,16, which is similar to findings in western countries1,2,3.
Is triple negative metastatic breast cancer curable? Triple-negative breast cancer has a dismal prognosis, especially once it has spread to other organs, due to the lack of effective treatments available at this time. Finding an effective treatment for metastatic triple-negative breast cancer remains an unmet medical need.
What is triple negative metastatic breast cancer? Triple-negative breast cancer (TNBC) accounts for about 10-15% of all breast cancers. The term triple-negative breast cancer refers to the fact that the cancer cells don’t have estrogen or progesterone receptors (ER or PR) and also don’t make any or too much of the protein called HER2.
How is metastatic triple-negative breast cancer treated? Triple-negative breast cancer (TNBC) doesn’t have estrogen or progesterone receptors and also makes too little or none of the HER2 protein. Because the cancer cells don’t have these proteins, hormone therapy and drugs that target HER2 are not helpful, so chemotherapy (chemo) is the main systemic treatment option.